Gynecologic oncology · 2026
Immunotherapy-induced thyroid dysfunction and diabetes mellitus in gynecologic oncology patients: a retrospective cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gonzalez Anna, Chalif Julia, O'Connor Reed, McLaughlin Eric, Morton Molly, Fulton Jessica, Velasquez Jessica, Cohn David E, Cosgrove Casey M, Copeland Larry J, Nagel Christa I, Backes Floor, O'Malley David M, Chambers Laura M
Аннотация
OBJECTIVES: We sought to characterize immune-related endocrine toxicities (IETs) in gynecologic oncology patients receiving immunotherapy (IO), including risk factors, onset and resolution characteristics, and clinical outcomes.
METHODS: This IRB-approved retrospective cohort study included all gynecologic oncology patients who received IO at a single institution between January 1, 2017, to January 1, 2023. Clinical characteristics, IO regimen, endocrine toxicities, management strategies, time to onset, resolution, and oncologic outcomes were abstracted from electronic medical records.
RESULTS: Among 333 patients, 128 (38.4%) developed an IET (immune-related endocrine toxicities). The most common IETs were hypothyroidism (31.2%, n = 104), hyperthyroidism (11.7%, n = 39), and insulin-dependent diabetes mellitus (2.4%, n = 8). Most toxicities were grade 1 (44.5%, n = 57) or grade 2 (50.8%, n = 65), while 4.7% (n = 6) were grade 3 or 4. Median time from IO initiation to IET diagnosis was 9.0 weeks (IQR, 5.4-18.7). Overall, 62.5% of patients with an IET required endocrine-directed therapy, and 56.3% required subsequent dose adjustment. Most IETs did not resolve during the median follow-up period of 16.4 months (67.2%, n = 86). Among IETs that resolved, median time to resolution was 8.1 weeks (IQR, 3.4-16.3). Pre-existing endocrine disorders were present in 43.8% of patients, most commonly hypothyroidism and diabetes. Among patients receiving endocrine-directed therapy, 51.9% required medication dose escalation during IO.
CONCLUSIONS: IETs are common among patients with gynecologic cancers receiving immunotherapy. While mostly low-grade, these events are usually chronic and frequently require medications or dose adjustments. These findings highlight the need for routine endocrine monitoring and long-term management strategies.
METHODS: This IRB-approved retrospective cohort study included all gynecologic oncology patients who received IO at a single institution between January 1, 2017, to January 1, 2023. Clinical characteristics, IO regimen, endocrine toxicities, management strategies, time to onset, resolution, and oncologic outcomes were abstracted from electronic medical records.
RESULTS: Among 333 patients, 128 (38.4%) developed an IET (immune-related endocrine toxicities). The most common IETs were hypothyroidism (31.2%, n = 104), hyperthyroidism (11.7%, n = 39), and insulin-dependent diabetes mellitus (2.4%, n = 8). Most toxicities were grade 1 (44.5%, n = 57) or grade 2 (50.8%, n = 65), while 4.7% (n = 6) were grade 3 or 4. Median time from IO initiation to IET diagnosis was 9.0 weeks (IQR, 5.4-18.7). Overall, 62.5% of patients with an IET required endocrine-directed therapy, and 56.3% required subsequent dose adjustment. Most IETs did not resolve during the median follow-up period of 16.4 months (67.2%, n = 86). Among IETs that resolved, median time to resolution was 8.1 weeks (IQR, 3.4-16.3). Pre-existing endocrine disorders were present in 43.8% of patients, most commonly hypothyroidism and diabetes. Among patients receiving endocrine-directed therapy, 51.9% required medication dose escalation during IO.
CONCLUSIONS: IETs are common among patients with gynecologic cancers receiving immunotherapy. While mostly low-grade, these events are usually chronic and frequently require medications or dose adjustments. These findings highlight the need for routine endocrine monitoring and long-term management strategies.